Trials / Recruiting
RecruitingNCT05964504
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (estimated)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Detailed description
Primary Aims: 1. To evaluate the feasibility of developing a histologic based registry for participants living with metastatic lobular breast cancer. 2. To understand the natural history, treatment patterns, and overall survival in patients with metastatic ILC using modern, real-world data. Secondary Aims: 1. To evaluate the correlation between imaging findings and disease progression. 2. To evaluate the correlation between ctDNA and disease progression. 3. To develop an ongoing platform for evaluating new imaging tools, tumor markers, and participant recruitment for clinical trials. Outline: Participants will be recruited to participate in the registry during a regularly scheduled clinic visit with their treating oncologist, and consented to participate at this time. At each evaluation time point, participants will have a blood draw performed. Participants will be followed until loss to follow up, death, or withdrawal from the registry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood Specimen | Blood will be drawn via venipuncture |
Timeline
- Start date
- 2023-12-20
- Primary completion
- 2036-02-28
- Completion
- 2036-02-28
- First posted
- 2023-07-28
- Last updated
- 2026-03-17
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05964504. Inclusion in this directory is not an endorsement.